Anna is a Vice President on the Life Sciences team, and focuses on identifying and evaluating new investment opportunities.
Anna joined Frazier Healthcare Partners in 2018, where she focuses on evaluating investment opportunities and creating new ventures in the life sciences area. She is a board observer for Amunix Pharmaceuticals, Inipharm, Lengo Therapeutics, and HilleVax.
Prior to joining Frazier, Anna was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Anna advised leading biotechnology and pharmaceutical companies on strategic planning, M&A, R&D, and business development strategy. Previously, Anna was an entrepreneurial fellow at Flagship Pioneering. In addition, she has been involved in several projects to spinout technologies in the life sciences space.
Anna received her Ph.D. in Systems Biology and A.B. in Biochemical Sciences from Harvard University, where she was a National Science Foundation Graduate Research Fellow. She also conducted research in systems medicine at Tsinghua University.
Harvard University (P.h.D.)
Harvard College (A.B.)